This post was written by OneMedPlace Team
OneMedResearch produces white papers exploring investment strategies abroad.
This white paper, entitled Investing in Swiss Life Sciences, explores the reasons for technological innovation in the region.
Known as a hotbed for medtech, Switzerland has emerged as an important source of biotech and pharma, due in part to the strong osmosis between private and public sector fostering innovation.
On the other side of company growth development, Switzerland is a source of capital, with a severely liquid institutional investor base and a significant presence of alternative funds and private money.
This white paper explores what makes Switzerland a unique market for investment and innovation, analyzing:
To download the report, click here.